Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors.
- DOI
- 10.2174/1389201020666181226123054
- Published
- 2018
- Container
- Current pharmaceutical biotechnology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.2174/1389201020666181226123054,
title = {Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors.},
author = {Guo Q and Yang Q and Li J and Liu G and Nikoulin I and Jia S},
year = {2018},
journal = {Current pharmaceutical biotechnology},
doi = {10.2174/1389201020666181226123054},
url = {https://doi.org/10.2174/1389201020666181226123054}
}RIS
TY - JOUR TI - Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors. AU - Guo Q AU - Yang Q AU - Li J AU - Liu G AU - Nikoulin I AU - Jia S PY - 2018 JO - Current pharmaceutical biotechnology DO - 10.2174/1389201020666181226123054 UR - https://doi.org/10.2174/1389201020666181226123054 ER -
APA
Q, G., Q, Y., J, L., G, L., I, N., & S, J. (2018). Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors.. Current pharmaceutical biotechnology. https://doi.org/10.2174/1389201020666181226123054
Source records
- pubmed · retrieved 2026-09-26T18:22:24.006Z